Infectious Diseases Collaboration and Licensing Deals 2020-2026

Description

Infectious Diseases Collaboration and Licensing Deals

Stop guessing. Start benchmarking real deals.

If you're working on an infectious disease deal, you don't need more opinions - you need evidence.

This report gives you direct access to 1,700+ real-world partnerships, so you can see exactly how deals are structured, valued, and negotiated across vaccines, antivirals, antibiotics, and emerging technologies.

Know what a "good deal" actually looks like

Without real benchmarks, you're negotiating in the dark.

With this report, you can:

Anchor negotiations with real precedent
See what companies are actually paying - not what they claim in press releases
Benchmark deal terms instantly
Compare upfronts, milestones, and royalty structures across relevant transactions
Avoid overpaying or underselling
Understand the realistic range for deals at your stage and in your space
Challenge counterpart assumptions with data
Walk into negotiations backed by hard evidence, not guesswork
See how deals are really written - not just announced
Most datasets stop at headlines. That's not enough.

This report gives you access to actual contracts, so you can see:

How rights are allocated
What partners commit to (and what they don't)
How payments are structured and triggered
Where risks and flexibilities sit
This is the detail that defines deal outcomes - and it's usually hidden.
Built for teams actively doing deals

Whether you're licensing, partnering, or evaluating opportunities, this report helps you:

Move faster with immediate access to relevant comparables
De-risk decisions using real transaction evidence
Strengthen internal alignment with credible market data
Negotiate from a position of strength
What you get
1,700+ infectious disease deals
Financial terms, including royalties where disclosed
Fully searchable deal database (by company, therapy, technology, stage)
Direct access to SEC-filed agreements
850+ pages of structured deal analysis
The bottom line
If you're making decisions on incomplete information, you're taking unnecessary risk.
This report gives you the data, benchmarks, and contract-level insight to structure better deals - and win them.
Request a sample or speak to us about how this can support your current deal work.

Product Code: CP2206

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Infectious diseases partnering by technology type
2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3. Infectious diseases partnering headline values
3.4. Infectious diseases deal upfront payments
3.5. Infectious diseases deal milestone payments
3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

4.1. Introduction
4.2. Most active in infectious diseases partnering
4.3. List of most active dealmakers in infectious diseases
4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

5.1. Introduction
5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by infectious diseases therapeutic target
Deal directory
Deal directory - Infectious diseases deals by company A-Z
Deal directory - Infectious diseases deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Infectious diseases partnering since 2020
Figure 2: Infectious diseases partnering by deal type since 2020
Figure 3: Infectious diseases partnering by industry sector since 2020
Figure 4: Infectious diseases partnering by stage of development since 2020
Figure 5: Infectious diseases partnering by technology type since 2020
Figure 6: Infectious diseases partnering by indication since 2020
Figure 7: Infectious diseases deals with a headline value
Figure 8: Infectious diseases deals with upfront payment values
Figure 9: Infectious diseases deals with milestone payment
Figure 10: Infectious diseases deals with royalty rates
Figure 11: Active infectious diseases dealmaking activity since 2020
Figure 12: Top infectious diseases deals by value since 2020